Consequently, VEGF/VEGFR blockade is thought to exert an anti-tumor immunomodulatory effect and has been shown to reduce MDSCs in tumors and blood in both preclinical tumor models and human cancers (71). This evidence concerns the gene VEGFA and cancer.